[1] QIN SK, SHEN F, ZHOU J.Expert consensus on the clinical application of donafenil in the treatment of hepatocellular carcinoma[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2022, 27(8): 749-757. [2] LI X, QIU M, WANG S, et al.A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours[J]. Cancer Chemother Pharmacol, 2020, 85(3): 593-604. [3] KEAM SJ, DUGGAN S.Donafenib: first approval[J]. Drugs, 2021, 81(16): 1915-1920. [4] YANG Y, ZHU H, LI Q.Partial response of donafenib as the third-line therapy in metastatic colon cancer: a case report[J]. Medicine (Baltimore), 2021, 100(37): e27204. [5] LIN YS, YANG H, DING Y, et al.Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial[J]. Thyroid, 2021, 31(4): 607-615. [6] JIANG HM.Progress in diagnosis and treatment of erythema multiforme[J]. Modern Medicine and Health Research(现代医学与健康研究电子杂志), 2019, 3(11): 9-11. [7] LU WH, GUO J, CAO DL, et al.Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion protein with glucocorticoid successfully treat Stevens-Johnson syndrome: a case report[J]. Chin J Lepr Skin Dis(中国麻风皮肤病杂志), 2021, 37(8): 525-527. [8] CHEN JJ, QIAN PP, CAO K, et al.Comparison and analysis of causality assessment method in China and Naranjo’s method in the evaluation of adverse drug reactions[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(8): 988-992. [9] Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Dermatology, et al. Guideline for primary care of drug eruption(2022)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2022, 21(9): 804-813. [10] WU ZH. Contemporary Dermatology(现代皮肤科学)[M]. Beijing: People’s Medical Publishing House, 2021: 463. [11] MANTOVANI A, ÁLVARES-DA-SILVA MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report[J]. Ann Hepatol, 2019, 18(5): 777-779. [12] AI L, XU Z, YANG B, et al.Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management[J]. Expert Rev Clin Pharmacol, 2019, 12(12): 1121-1127. [13] MIZUKAMI Y, SUGAWARA K, KIRA Y, et al.Sorafenib stimulates human skin type mast cell degranulation and maturation[J]. J Dermatol Sci, 2017, 88(3): 308-319. |